Core Insights - Aurora Cannabis Inc. is investing over five years in operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany, aimed at enhancing flower growth capacity, product quality, and cost efficiency [1][2][6] - The upgrades will strengthen supply chain resilience and expand domestic capabilities in EU-GMP certified manufacturing to meet the growing demand for high-quality medical cannabis in Europe [2][3] Investment Details - The investment will include commissioning additional grow rooms, new irrigation and lighting systems, and transitioning to hang dry and dry trim methods [2][3] - This initiative is part of Aurora's commitment to operational excellence and long-term growth in the European market [2] Market Position - Aurora Leuna is one of only three licensed cultivation facilities in Germany, playing a crucial role in supplying locally grown medical cannabis to an expanding patient base [3] - The expansion will allow Aurora to grow additional cultivars from its genetics library, positioning the company to serve international markets at high standards [3] Company Overview - Aurora Cannabis Inc. operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand, with a focus on high-quality products [4] - The company’s brand portfolio includes various medical and adult-use brands, and it has a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants [4]